 The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection estimated date of infection within the last 90 days. The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtricitabinetenofovir during acuteearly HIV infection leads to protection of CD4 T cells and other immune cells in the peripheral blood and lymphoid tissue from infection. 